AAI/Cambridge Major Labs to rehouse anaytical services in new MO facility

By Dan Stanton

- Last updated on GMT

St Louis, Missouri. Image: iStock/knowlesgallery
St Louis, Missouri. Image: iStock/knowlesgallery

Related tags Investment

Increased client demand for analytical testing has driven merged CDMO AAIPharma/Cambridge Major Laboratories to invest $11m into a new facility in Missouri.

In 2013, the contract development and manufacturing organisations AAIPharma Services and Cambridge Major Laboratories merged and told this publication​ there would be future investment in capital expansion of new capabilities to further support the growing demand from its joint customer base.

And last week, the entity announced it was investing $10.7m (€9.7m) to build a new facility at its Cortex Innovation Center in St Louis, Missouri, to rehouse its current analytical testing services currently located nearby.

The CDMO said the new site was a response to increased customer demand and the growing trend of analytical testing outsourcing from pharma and biopharma clients. CEO Stephan Kutzer added the relocation comes at a critical time for his company's growth:

“Analytical testing is an instrumental pillar of our company and we are excited to provide our customers and the market with innovative testing solutions as part of our overall service offering including our other pillars in API, Drug Product and Development Services.”

Construction is set to be completed by the end of this year, with the first quarter 2017 seeing a transition period from the existing facility, with AAI/CML pledging there will be no disruption to any client projects.

It will provide new testing capabilities, such as glass and plastic containers testing for pharmaceutical use, elemental impurities, disinfectant qualification and efficacy studies, complementing analytical current services being offered by the firm.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us